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Alternate explanation of the additive protective
effects of regional infusion of hypothermic saline
and adenosine solutions
To the Editor:
We read with great interest the two related, timely, and
informative articles from the same group in Charlottesville,
Virginia, about which we would like to make some comments.
The first article was titled “Complete Prevention of Spinal
Cord Injury by Means of Regional Infusion With
Hypothermic Saline and Adenosine,” by Herold and associ-
ates (J Thorac Cardiovasc Surg 1994;107:536-42).
1. The authors state in the “Results” section that “differ-
ences in the core body temperature of all groups were slight,
and the differences were not statistically significant (p >
0.05).” However, we believe that had the esophageal instead
of the rectal temperature been monitored, the core tempera-
ture would have dropped despite the warming blanket. In the
model described by the authors, the rectal temperature is
monitoring most likely the temperature of a body segment
excluded from the circulation, since a vascular clamp was
applied above the aortic bifurcation, and no mention is made
regarding its relationship to the inferior (posterior) mesen-
teric artery. (Had the inferior mesenteric artery been included
in the isolated aortic segment, the rectal temperature certain-
ly would have dropped significantly just as the spinal cord
temperature did). We monitor both esophageal and rectal
temperature, and even smaller volumes of solutions at ambi-
ent temperature than the authors used (8°C, 30 mL/kg in 10
minutes), given over a longer period, have been accompanied
by esophageal temperature drop not compensated immediate-
ly by the warming table–heating lamp combination. Also, we
have found that rectal temperature is easily influenced (on the
overheating side) by the temperature of the warming table
despite keeping it at only 43°C, not 50°C, perhaps by heat
convection.
2. Although we believe, like the authors, that the protective
effects of adenosine were additive to those obtained by
hypothermia alone, the lack of a control group receiving only
cold saline solution without adenosine for the same ischemic
period does not permit us to even begin to discern the relative
roles played by each one of them. Minimal degrees of
hypothermia, even without added pharmacologic means,
would probably provide sufficient protection for 40 minutes
of ischemia. We have found that esophageal temperature
closely reflects spinal cord temperature during surface-
induced hypothermia, and an esophageal temperature of
29.5°C can protect during 60 minutes of ischemia in the rab-
bit model of spinal cord ischemia.1
3. In general, the protective effects of adenosine in the cen-
tral nervous system have been ascribed to A1 receptors sensi-
tive to minute concentrations of adenosine, on the order of
micromoles per liter. A1 receptors decrease the release of
ischemia-induced excitatory neurotransmitters by decreasing
the activity-evoked membrane depolarization induced by
decreasing the opening of voltage-dependent Ca++ channels.
They are also known to hyperpolarize the membrane by
opening the Cl– channels.2,3 The rather large dose of adeno-
sine used by the authors is most certainly activating the A2
receptors, sensitive to millimolar concentrations of adeno-
sine. A2 receptors are known to release taurine mediated by
cyclic adenosine monophosphate in cultured glial cells since
19884 besides the vascular, leukocyte, and platelet effects dis-
cussed by the authors. Taurine is a β-amino acid known to
also hyperpolarize membranes by a mechanism similar to
that of adenosine and reportedly to have marked inhibitory,
anticonvulsant, antioxidant, and free-radical scavenging
effects.5-7 Taurine is released by adenosine in all areas of the
brain in in vivo animals,8 including areas with predominant-
ly A1 receptors, such as the hippocampus, in a dose-depen-
dent manner.9 Although we have not proven that taurine is
released in the spinal cord as well, there are no reasons to
believe that it would not be.
4. Adenosine was administered essentially after initiation of
ischemia. Once ischemia occurs, it is unlikely that substrate
salvage based on rephosphorylation will be the modus operan-
di, since rephosphorylation will require an intact aerobic
metabolic machinery to be most effective, and such a mecha-
nism most likely is not present during ischemia. The adeno-
sine triphosphate (ATP) synthesis under anaerobic conditions
is ineffective and very limited. We believe that the substrate
salvage reported in myocardial protection studies alluded to
by the authors is the result of the inhibitory, hyperpolarizing
effects of adenosine and/or taurine, universal in all tissues,
myocardium included, leading to ATP conservation rather
than ATP resynthesis from adenosine, adenosine monophos-
phate, or adenosine diphosphate during ischemia. To properly
determine the role adenosine would play in facilitating the
rephosphorylation after reperfusion requires another group in
which adenosine is given after reperfusion only.
5. Myocardial protective effects of systemically adminis-
tered taurine have been documented.10 We have found that
protective effects of systemically administered taurine given
before ischemia are not limited to the myocardium. Indeed,
we found taurine to enhance significantly the protective
effects of hypothermia in a rabbit model of spinal cord
ischemia (manuscript in press). Hypothermia is also known
to hyperpolarize membranes. Thus we suggest that the com-
bined effects of adenosine and the released taurine would
result in further increase of the hypothermia-induced hyper-
polarization of the membrane as the alternate explanation of
the additive protective effects of adenosine and hypothermia
observed by the authors.
6. Although the authors explain the transient hypotension
as a phenomenon of washout of the adenosine through the
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aorta, the most logical explanation may be related to the
rather short half-life (<10 seconds) of adenosine in blood
because of the very effective uptake by the red cells.11
The second article on which we would like to comment, by
Ross and associates, is titled “Hypothermic Retrograde
Venous Perfusion With Adenosine Cools the Spinal Cord and
Reduces the Risk of Paraplegia After Thoracic Aortic
Clamping” (J Thorac Cardiovasc Surg 2000;119:588-95).
1. Although apparently no statistically significant differ-
ence was reported between the adenosine group (III: Tarlov
score 4.7 ± 0.2) and the plain saline solution group (II: Tarlov
score 3.8 ± 0.4), no explanation is offered regarding the neu-
rologic recovery in group III, which seems to us significantly
better (P < .002).
2. Somatosensory evoked potentials (SSEPs) ceased signif-
icantly faster in the groups receiving regional infusion of
hypothermic solution (II and III) than in the normothermic
ischemia group (I), corroborating in the spinal cord a widely
known observation in the nonischemic brain (the electroen-
cephalogram becomes a straight line below 24°C-25°C) that
hypothermia markedly decreases all neural activity, transmis-
sion included. However, no differences were observed
between groups II and III (P = .86 according to our analysis
of the presented data). The authors’ conclusion that electrical
silence is the major determinant of protection seems not to be
substantiated by the significantly different neurologic out-
comes in two groups, in which SSEPs ceased within compa-
rable times after hypothermic perfusion.
3. The lesser amplitude of the postreperfusion returned
SSEP of group III (85% vs 90% of group II; whether differ-
ences would be statistically significant could not be calculat-
ed since no SDs are provided) was not unexpected, and the
better neurologic outcome can be explained by the same com-
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Should methylene blue be the drug of choice to treat
vasoplegias caused by cardiopulmonary bypass and
anaphylactic shock?
To the Editor:
Yiu, Robin, and Pattison1 presented a rapid reversal of
refractory hypotension with methylene blue after cardiopul-
monary bypass (CPB). I would like to reinforce this kind of
therapeutic approach, not only for low systemic vascular
resistance (SVR) after CPB, but also for other types of vaso-
plegias, including anaphylactic shock.
My colleagues and I2 reported the restoration of SVR with
the use of methylene blue in 6 patients after cardiac surgery
with and without CPB. In the immediate postoperative peri-
od, all patients had tachycardia, oliguria, good peripheral per-
fusion, and important systemic arterial hypotension not
responsive to large doses of infused catecholamines.
Hemodynamic analysis, done by the thermodilution tech-
nique (Swan-Ganz; Baxter Healthcare Corp, Santa Ana,
Calif), showed a profile compatible with systemic inflamma-
tory response syndrome, with a mean SVR index of 868 dina
· s · cm5. Methylene blue was administered to block the action
of nitric oxide inhibiting the soluble guanylate cyclase at
doses of 1.5 mg/kg during 1 hour of intravenous infusion.
The systemic vascular tone restoration (SVR index = 1693
dina · s · cm5 with normal arterial pressure and clinical per-
formance) was effective and fast, showing methylene blue as
a pharmacologic tool that improves the morbidity and mor-
tality in systemic inflammatory response syndrome.
Methylene blue did not affect cardiac output or pulmonary
vascular resistance in those patients. This clinical experience
was started in 1994 with the use of methylene blue in des-
perate situations in the operating room and early hours of the
postoperative period. Since the presentation of these hemo-
dynamic data, methylene blue has been widely used in
Brazil.2 Trying to find cause-effect clues, we identified some
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